OTTAWA, March 16 (Xinhua) -- Canada's National Advisory Committee on Immunization (NACI) announced on Tuesday that the Oxford-AstraZeneca COVID-19 vaccine is both safe and effective for people over age 65.
The committee said real-world evidence has demonstrated that the vaccine is safe and effective in older people, particularly against severe illness from COVID-19 and hospitalization.
The announcement is different from a recommendation made by the NACI itself on March 1, when its panel of vaccine experts said AstraZeneca hadn't included enough people over the age of 65 in its clinical trials.
The committee said three "real-world effectiveness studies" helped inform its decision to change the recommendations, including evidence from Britain, which has been administering the vaccine to people over 65 years and older since January.
The NACI initially recommended that people over the age 65 should be prioritized for the Pfizer-BioNTech and Moderna vaccines instead of the AstraZeneca, because of "limited information on the efficacy of this vaccine in this age group."
On Monday, Germany, France, Italy and Spain joined a list of European countries to suspend use of the AstraZeneca vaccine following reports of blood clots in some recipients.
AstraZeneca has said that a review of 17 million people who have received their vaccine in Europe and Britain found no evidence of an elevated blood clotting risk.
On Monday, Prime Minister Justin Trudeau assured Canadians that the AstraZeneca vaccine is safe for use.
"Health Canada and our experts and scientists have spent an awful lot of time making sure every vaccine approved in Canada is both safe and effective," Trudeau said.
Health Canada approved the AstraZeneca vaccine for use in anyone 18 years or older in late February. It became the third COVID-19 shot green-lighted in Canada, joining vaccines from Pfizer-BioNTech and Moderna.
Canada's initial 500,000 doses of the AstraZeneca COVID-19 vaccine have been manufactured by the Serum Institute of India.
Health Canada said that the AstraZeneca vaccine has an efficacy of 62.1 percent among people 18 to 64 years old.
In total, Canada is reportedly scheduled to receive 23.9 million doses of the vaccine.
As of Monday evening, more than 3.1 million COVID-19 vaccine doses were administered across the country, meaning approximately 4.2 percent of the Canadian population has been immunized against the virus.